AstraZeneca PLC (AZN)vsThe Ensign Group Inc (ENSG)
AZN
AstraZeneca PLC
$169.51
+2.88%
HEALTHCARE · Cap: $263.78B
ENSG
The Ensign Group Inc
$184.11
+8.62%
HEALTHCARE · Cap: $10.01B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 1018% more annual revenue ($61.37B vs $5.49B). AZN leads profitability with a 17.0% profit margin vs 6.9%. AZN appears more attractively valued with a PEG of 1.22. ENSG earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
ENSG
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$194.96
Current Price
$169.51
$25.45 discount
Margin of Safety
-39.9%
Fair Value
$151.53
Current Price
$184.11
$32.58 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
17.3% revenue growth
Areas to Watch
Moderate valuation
2.5% earnings growth
Distress zone — elevated risk
Moderate valuation
6.9% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.22 suggests the stock is reasonably priced for its growth.
Bull Case : ENSG
The strongest argument for ENSG centers on Revenue Growth. Revenue growth of 17.3% demonstrates continued momentum. PEG of 1.38 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, EPS Growth, Altman Z-Score.
Bear Case : ENSG
The primary concerns for ENSG are P/E Ratio, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while ENSG is a growth play — different risk/reward profiles.
ENSG carries more volatility with a beta of 0.69 — expect wider price swings.
ENSG is growing revenue faster at 17.3% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (62/100 vs 62/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
The Ensign Group Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company is headquartered in San Juan Capistrano, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?